Biosolution Co (XKRX:086820) Debt-to-Asset : 0.42 (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Biosolution Co Debt-to-Asset?

Biosolution Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩27,268 Mil. Biosolution Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩971 Mil. Biosolution Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was ₩67,464 Mil. Biosolution Co's debt to asset for the quarter that ended in Dec. 2024 was 0.42.

Biosolution Co Debt-to-Asset Historical Data

The historical data trend for Biosolution Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosolution Co Debt-to-Asset Chart

Biosolution Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.03

0.30

0.36

0.39

0.42

Biosolution Co Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.39	0.41	0.42	0.37	0.42

Competitive Comparison of Biosolution Co's Debt-to-Asset

For the Biotechnology subindustry, Biosolution Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biosolution Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biosolution Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Biosolution Co's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Biosolution Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Biosolution Co's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(27268.08	+	970.606)	/	67464.08
	=	0.42

Biosolution Co's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(27268.08	+	970.606)	/	67464.08
	=	0.42

Biosolution Co (XKRX:086820) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Biosolution Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Biosolution Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosolution Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosolution Co Ltd (XKRX:086820) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Gongneung-Ro 232, Nowon-gu, 5th Floor, Room 519, Seoul Technopark, Seoul, KOR

Website

http://www.biosolutions.co.kr

Biosolution Co Ltd is a Korean company offering Cell-Based Biotechnology. It is engaged in manufacturing and selling cell therapy products, and developing cell therapeutics technology. Its main areas include cell-based therapeutics with their background in somatic and stem cell technology, and the manufacturing, sales, and R&D of human tissue models for screening toxicity and efficacy with tissue engineering technology.

Biosolution Co Headlines

No Headlines